Amarin Corporation (NASDAQ:AMRN) commented on recent therapeutic advances for patients with elevated triglycerides, asserting that its flagship VASCEPA/VAZKEPA (icosapent ethyl) franchise remains strongly positioned to benefit from broader category commercialization efforts.
The company noted that VASCEPA has been prescribed more than 25 million times in the United States, where it holds FDA approval for two distinct indications: treatment of severe hypertriglyceridemia (triglycerides ≥500 mg/dL) as an adjunct to diet, and cardiovascular risk reduction in adults with established cardiovascular disease or diabetes mellitus and additional risk factors as an adjunct to maximally tolerated statin therapy.
Amarin highlighted the landmark REDUCE-IT cardiovascular outcomes trial, which enrolled 8,179 patients and demonstrated a 25% relative risk reduction in major adverse cardiovascular events with icosapent ethyl compared with placebo.
On the global front, the company underscored its 2025 exclusive license agreement with Recordati Rare Diseases for commercialization of VAZKEPA across 59 countries outside the United States.
The product is now available in more than 20 countries, reflecting steady expansion of its international footprint.
Management expressed confidence that ongoing scientific and clinical developments in triglyceride management, coupled with VASCEPA/VAZKEPA's established efficacy and safety profile, position the franchise favorably for continued growth and increased adoption in both established and emerging markets.